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Abstract
Background: More than 20% of human transcripts have naturally occurring antisense products
(or natural antisense transcripts – NATs), some of which may play a key role in a range of human
diseases. To date, several databases of in silico defined human sense-antisense (SAS) pairs have
appeared, however no study has focused on differential expression of SAS pairs in breast tissue.
We therefore investigated the expression levels of sense and antisense transcripts in normal and
malignant human breast epithelia using the Affymetrix HG-U133 Plus 2.0 and Almac Diagnostics
Breast Cancer DSA microarray technologies as well as massively parallel signature sequencing
(MPSS) data.
Results: The expression of more than 2500 antisense transcripts were detected in normal breast
duct luminal cells and in primary breast tumors substantially enriched for their epithelial cell
content by DSA microarray. Expression of 431 NATs were confirmed by either of the other two
technologies. A corresponding sense transcript could be identified on DSA for 257 antisense
transcripts. Of these SAS pairs, 163 have not been previously reported. A positive correlation of
differential expression between normal and malignant breast samples was observed for most SAS
pairs. Orientation specific RT-QPCR of selected SAS pairs validated their expression in several
breast cancer cell lines and solid breast tumours.
Conclusion: Disease-focused and antisense enriched microarray platforms (such as Breast Cancer
DSA) confirm the assumption that antisense transcription in the human breast is more prevalent
than previously anticipated. Expression of a proportion of these NATs has already been confirmed
by other technologies while the true existence of the remaining ones has to be validated.
Nevertheless, future studies will reveal whether the relative abundances of antisense and sense
transcripts have regulatory influences on the translation of these mRNAs.
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Background
Naturally occurring antisense transcripts (NATs) are
sequences complementary to other transcripts and were
first identified in prokaryotes and viruses, where their
expression influences mRNA transcription, processing
and translation [1]. Over the past few years, antisense
transcription in human and other eukaryotic genomes has
become increasingly evident due to the availability of
high throughput sequencing technologies and strand-spe-
cific tiling oligonucleotide arrays [2-4]. The rigorous anal-
ysis of the human genome by the ENCyclopedia Of DNA
Elements (ENCODE) project fortified the notion that
transcription is substantially more complex than previ-
ously conceived and that at least 15% of all transcripts
could derive from antisense transcription [5]. So far more
than 10,000 potential sense/antisense (SAS) transcript
pairs have been identified in both human and mouse
genomes [6] and several antisense containing databases
such as antiCODE have been published [7]. While the
majority of studies have focused on the mapping and evo-
lutionary aspect of SAS pairs, only a few studies have inter-
rogated and validated their abundance in different human
tissues [2,6,8-10]. Here we report for the first time a com-
prehensive analysis of SAS pairs with regards to their dif-
ferential expression in the normal and malignant breast
epithelium.
A discrete function of SAS pairs in human tissues has not
been identified, although their regulatory activity on pro-
tein expression at diverse levels, such as alternative splic-
ing, post-transcriptional regulation, transport and
epigenetic imprinting as well as transcriptional and trans-
lational interference through annealing to complemen-
tary sequences has been postulated [11]. Since some
functional data for their involvement in developmental
processes have recently emerged [12,13], their role in
malignant transformation of human tissues may be fore-
seen.
Initially, NATs were identified using large collections of
mRNA, genomic and EST sequences, as well as expression
data from methods such as serial analysis of gene expres-
sion (SAGE) and massively parallel signature sequencing
(MPSS) [6,14-16]. By using these sequencing data for the
identification of NATs, stringent criteria were applied to
determine correctly the orientation of each sense or anti-
sense transcript relative to its genomic sequence. Over the
last few years microarray based experiments have vali-
dated the prevalence of NATs in different human and
mouse tissues [4,5,8,10]. Using strand-specific microarray
probes, Oeder et al. interrogated the abundance of many
different NATs based on the mouse Affymetrix MOE430
microarray dataset [8], while Ye et al. identified several
hundred NATs in 19 human cell lines [2]. Ge and col-
leagues extended the use of oligonucleotide based micro-
arrays for the analysis of NAT expression by altering the
protocol for cDNA synthesis and thereby strongly sup-
porting the observation that encoding of transcripts on
both DNA strands often results in complementary mRNAs
[17]. Recently, another human microarray chip based on
the Affymetrix Genechip platform – namely the Breast
Cancer DSA – was developed by Almac Diagnostics [18].
The design methodology of the DSA range of research
tools has previously been described [19]. In brief, the
Breast Cancer DSA microarray was designed utilising
breast cancer-specific sequence information consisting of
full length public mRNAs and contigs generated by the
assembly of a range of public and proprietary EST data-
sets. The DSA is classified as a discovery platform and its
content ranges from well-characterised transcripts to
those whose function is currently unknown. Furthermore,
the content includes a large number of probe sets specific
for the detection of antisense transcripts in addition to a
significant amount of sense transcript information not
found on other commercially available microarrays. It is
therefore ideally suited to investigate the sense and anti-
sense transcriptome of breast cancer.
In this study, we have used the Breast Cancer DSA research
tool in conjunction with the Affymetrix HG-U133 Plus
2.0 GeneChip and MPSS data sets of our established dif-
ferential tumour epithelial transcriptome [20] to analyze
the expression of SAS pairs in immunomagnetically sepa-
rated normal human luminal epithelial cells and primary
breast cancers substantially enriched for their neoplastic
epithelial component. The aim of the current study was
not only to identify SAS pairs expressed in the epithelial
cells of human breast tissue, but also to validate their
expression signature using several different technologies.
Our particular focus was upon SAS pairs with deregulated
expression in mammary epithelial cells, and to ascertain
whether the expression of the antisense transcripts could
be detected in several different breast cell lines and solid
primary breast tumours. Generating the first comprehen-
sive dataset of SAS pairs in epithelial breast tissue, our
analysis has also shed light on the nuances of antisense
and sense transcription.
Results
Microarray probe sets and MPSS tags with sense and 
antisense orientation
The basis of all cross-platform comparison is reliability of
annotation and mapping of microarray features and tag
sequences, especially if transcripts from the sense or anti-
sense orientation are to be distinguished. To ensure the
correct annotation, probesets from both microarray plat-
forms, as well as MPSS tags, were mapped by sequence
alignment to a human transcriptome (HTR) database that
was previously used for a multiple platform comparison
study [20,21]. To be included for further analysis, strin-BMC Genomics 2009, 10:324 http://www.biomedcentral.com/1471-2164/10/324
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gent filtering criteria were applied to the probe sets and
MPSS tags: firstly, probe sets and MPSS tags that could not
be mapped to a HTR cluster or which aligned in silico to
several clusters were eliminated; secondly, probe sets had
to exclusively detect either the sense or antisense tran-
script – which was determined by the orientation of align-
ment of the probes or tags to the HTR clusters.
Both microarrays had approximately the same number of
microarray features printed, of which 33,355 out of
60,854 (54%) and 38,047 out of 54,613 (69%) probe sets
were unambiguously mapped to a HTR cluster in sense
orientation, for the Breast Cancer DSA and Plus 2.0,
respectively (Table 1). In contrast, 8,426 out of 60,854
(14%) probe sets on Breast Cancer DSA could potentially
detect antisense transcripts which is more than double
than the number detected by the Plus 2.0 (3,476 out of
54,613 or ≈ 6%) (Table 1). Despite the fact that the overall
magnitude of transcript detection by MPSS was much
smaller than those of the two microarray platforms, the
percentage of tags mapping to the sense strand to the over-
all detected sequences was similar to the microarray plat-
forms (69%; 13,611/19,794). Due to the MPSS
technology and our stringent criteria for inclusion as a
potential antisense detectable tag, only 215/19,794 (1%)
MPSS tags could potentially be derived from antisense
transcripts (Table 1).
Based on the HTR database, transcript coverage of sense
and antisense probes of these three technologies was com-
pared. Since both the Affymetrix probesets and the HTR
database were based solely on public sequence data, the
Plus 2.0 had the highest coverage of sense-mapped fea-
tures. 16,549 (78%) of those HTR clusters were also rep-
resented on Breast Cancer DSA, as were an additional
1,287 clusters not detected on the Plus 2.0 (Table 1). The
limitation of the MPSS sequencing technology became
apparent in this comparison, identifying only a third of all
sense transcripts represented on these microarray chips
(7,856 HTR common with Plus 2.0; and 7, 878 HTR clus-
ters with Breast Cancer DSA). Interestingly, when the cov-
erage of antisense transcripts was compared between these
three technologies, a different picture was obtained. The
majority of antisense-containing HTR clusters was found
on the Breast Cancer DSA. Out of the 6,358 antisense-con-
taining HTR clusters 1,753 overlapped with the Plus 2.0
and 101 HTR clusters were also identified by MPSS, illus-
trating the enrichment of antisense transcripts on the
Breast Cancer DSA microarray platform. The full HTR
mapping information for the DSA microarray features [see
Additional file 1], Plus 2 microarray features [see Addi-
tional file 2], and MPSS tags [see Additional file 3] are pro-
vided, and may provide a useful resource not only for
inclusion in current antisense databases, but also to inter-
rogate possible antisense transcription in several human
tissues and in published human expression datasets. HTR
database sequences are available on request.
To determine which of these antisense strand-matching
microarray features showed expression in the human
breast epithelium, the absence or presence calls for all
probe sets on both microarray platforms in either the nor-
mal luminal epithelial or the malignant breast epithelial
sample were established using the MAS5 algorithm.
Microarray features were included for further studies if at
least two out of three technical replicates per platform
agreed in their present calls, while MPSS tags were kept
when their tag count was at least 3 tags per million. Their
corresponding HTR cluster identifier was used to repre-
sent MPSS tags and microarray features. It was noted that
more than 60% of all probe sets passed the present call cri-
teria on the Breast Cancer DSA, only 39% had a concord-
ant present call on the Plus 2.0. As a next step, the sense
and the antisense transcriptomes of the normal and the
malignant breast epithelia were compared. Table 2. shows
an initial comparison of present calls obtained using the
two microarray platforms and MPSS in both normal and
malignant cell-lines. These numbers provide an initial
view of the number of transcripts detectable by each of the
three technologies.
As shown in Figure 1, the two microarray platforms had a
concordance of ~9,000 transcripts in the normal setting,
but nearly five times more transcripts were detected specif-
ically on the breast tissue specific Breast Cancer DSA
microarray platform in the normal and malignant epithe-
lium (Figure 1). Furthermore, expression profiles
obtained by the Breast Cancer DSA identified three times
Table 1: Sense and antisense mapping of probe sets and sequence tags
SENSE ORIENTATION ANTISENSE ORIENTATION
Plus 2.0 DSA MPSS Plus 2.0 DSA MPSS
Plus 2.0 21,078 HTR 2,995 HTR
DSA 16,549 HTR 17,737 HTR 1,753 HTR 6,358 HTR
MPSS 7,856 HTR 7,878 HTR 8,452 HTR 51 HTR 101 HTR 203 HTR
Numbers of representative human transcriptome clusters (HTR) Mapping of the Affymetrix HG U133 Plus 2.0 GeneChip (Plus 2.0) probe sets, Almac 
Diagnostics Breast Cancer DSA (DSA) probe sets and massively parallel signature sequencing (MPSS) sequence tags to the human transcriptome clusters 
(HTR) in either sense or antisense orientation.BMC Genomics 2009, 10:324 http://www.biomedcentral.com/1471-2164/10/324
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Table 2: HTR mapped probesets and tags called present.
Total number of 
probesets 
mapped to HTR
Total mapped 
probesets present in 
sense normal breast 
epithelium
Total mapped 
probesets present in 
antisense normal 
breast epithelium
Total mapped 
probesets present in 
sense malignant breast 
epithelium
Total mapped 
probesets present in 
antisense malignant 
breast epithelium
DSA 41,781
(100%)
12,330
(29%)
2,407
(5.8%)
13,408
(33.3%)
2,728
(6.5%)
Plus 2.0 41,523
(100%)
9,655
(23.2%)
433
(1%)
10,447
(25.2%)
131
(0.3%)
MPSS 13,826
(100%)
5,614
(40%)
94
(0.7%)
7,329
(53%)
155
(1.1%)
Total number of probesets/tags mapped to the HTR database and the number of present calls seen in normal and malignant breast epithelium in 
both sense and antisense orientations. These numbers indicate the actual detections levels of each technology.
Overlay of expression detection between MPSS and microarray for sense and antisense transcripts malignant and normal  breast epithelium Figure 1
Overlay of expression detection between MPSS and microarray for sense and antisense transcripts malignant 
and normal breast epithelium. Human transcriptome clusters (HTR) were used to measure the concordance in detecting 
sense and antisense transcripts for the Breast Cancer DSA (green), Affymetrix HG U133 Plus 2.0 (blue) and MPSS (red) in both 
the malignant breast epithelium and normal luminal epithelium. The presence of a MPPS tag was determined if a MPSS tag had 
at least a count of 3 tpm in these samples. For the two microarray platforms, a HTR cluster was called present when its con-
taining sense (top section) or antisense (bottom section) probe set obtained a present calls with the MAS5 algorithm.BMC Genomics 2009, 10:324 http://www.biomedcentral.com/1471-2164/10/324
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more transcripts found by MPSS than the Affymetrix plat-
form. This difference between the generic Affymetrix Plus
2.0 and the tissue-specific Breast Cancer DSA became even
more apparent when antisense-containing HTR clusters
were compared. While 43% of all antisense-detecting
probes sets obtained a present call, only 14% on the Plus
2.0 could be detected, corresponding to the unique detec-
tion of > 2,000 antisense-containing HTR clusters in the
normal and the malignant breast epithelium by Breast
Cancer DSA. For the DSA platform, 2452 antisense detect-
ing probe sets were in common between the normal and
the malignant epithelium, of which 868 showed more
than two-fold difference in expression level with a pValue
< 0.05. In contrast, 344 Affymetrix probe sets mapping to
antisense transcripts were detectable in normal and malig-
nant breast epithelium, of which 60 passed the same cri-
teria, and only 48 MPSS tags showed different expression
level.
Selecting those HTR clusters that mapped solely in anti-
sense orientation and were detected by at least 2 of the 3
technologies created a set of 431 'robust' antisense
sequences. Sequences could be detected in both the nor-
mal and the malignant setting or in either setting individ-
ually [see Additional file 4]. As shown in Figure 1, the
majority of these commonly represented antisense HTR
clusters were represented on the Breast Cancer DSA with
the exception of one, which was only detected by the Plus
2.0 and MPSS in the normal luminal breast sample.
Novel sense-antisense pairs in the human breast tissues
Having established a robust set of antisense containing
HTR clusters encompassing 431 antisense transcripts, we
Alignment of SAS pairs on genome Figure 2
Alignment of SAS pairs on genome. Exemplary screenshot of the contig view panel from the ENSEMBL Genome Browser 
for DCBLD2 (A), KRT81 (B) and MMP24 (C) illustrating probesets overlapping in sense and antisense orientation. SAS pairs 
are shown as red blocks, aligning to the genome (chequered bars) and known or predicted genes. A leftward arrow denotes 
alignment to the reverse strand of the genome whilst a rightward arrow represents alignment to the forward strand. Arrows 
are labeled with the DSA probeset ID representative of the transcript.
BRMX.4806C4n3_s_at
BRRS.3184_at
BRRS.13649_at
BRAD.31334_at
BRRS.6579_at
BRAD.24068_at
< DCBLD2
A
B
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interrogated how many of those had a corresponding
sense transcript also represented on the Breast Cancer
DSA. Sense and antisense transcript pairs were defined
when their sequence overlapped on opposite strands of
the HTR database (see Figure 2). According to our criteria,
257 SAS pairs were identified. Galante et al. published a
comprehensive study on antisense sense transcripts
derived from publicly available sequencing data [6]. To
establish if our SAS pairs had been reported previously,
their sequences were analysed against the Galante data-
base. Interestingly, only 94 of the 257 SAS pairs produced
matches against the database, while the remaining 163
produced no significant alignments and can therefore be
considered as novel or previously unidentified. Probeset
mapping for the 163 HTRs is provided [see Additional file
5].
As a next step, we wanted to interrogate if the antisense
and sense transcripts of the SAS pairs showed similar
expression patterns in the breast epithelium. The differen-
tial expression between the normal and the malignant
breast epithelium for all SAS pairs was established and
only probe sets whose differential expression had a signif-
icance level below 0.05 were used. When the Pearson's
correlation coefficients for the log2 ratios of our SAS pairs
were calculated, all SAS pairs showed a positive correla-
tion as shown in Figure 3.
Confirmation of differentially expressed SAS pairs by 
strand-specific qPCR
Since none of the identified SAS pairs exhibited an oppo-
site fold change between the normal and the malignant
breast epithelium, we wanted to explore further whether
these SAS pairs were exclusively showing positive differen-
tial expression patterns. Three of the 163 novel SAS pairs
were randomly selected and strand-specific RT-PCR used
to measure their expression. The 3 pairs, corresponding to
discoidin, CUB and LCCL domain containing 2
(DCBLD2, NM_080927.3), matrix metallopeptidase 24
(MMP24, NM_006690.3) and keratin 81 (KRT81,
NM_002281.3) had their expression interrogated in 16
breast cancer cell lines and ten solid primary breast
tumours (Figure 4). To distinguish expression coming
from the sense or the antisense strand, the first strand
cDNA synthesis of the RT-PCR was set up either with the
sense primer (generating cDNA from sense strand mRNA
transcripts) or the antisense primer (generating cDNA
from RNA from the antisense strand). FAM labeled fluo-
rescent probes for each gene were used to determine the
relative expression levels of the sense and antisense by
Correlation of differential gene expression for SAS pairs Figure 3
Correlation of differential gene expression for SAS pairs. The differential gene expression between the normal and the 
malignant breast epithelium was determined for all sense and antisense transcripts of the SAS pairs. Using Pearson's correla-
tion, the log2 expression ratios of the sense transcripts were compared with the log2 expression ratios of the antisense tran-
scripts for each SAS pair.
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qPCR. KRT81 showed similar expression patterns in all
tested samples with regards to sense and antisense tran-
scription and overall expression levels. In contrast,
DCBLD2 and MMP24 showed significantly higher expres-
sion ratios in the solid tumours in comparison with the
breast cancer cell lines. Furthermore the sense and anti-
sense transcripts of DCBLD2 had different expression lev-
els in BT474 and T47D, two hormone-receptor positive
luminal-specific breast cancer cell lines. When the expres-
sion of the antisense and sense MMP24 transcript was
interrogated, opposite expression levels were observed in
five breast cancer cell lines (namely MDA-MB-231 and
HMT3552 of basal-subtype; and BT474, MDA-MB-453,
SKBR5 and SKBR7 of luminal-subtype) as well as in five
solid breast tumours.
Discussion
The initial goal of our study was to perform comparative
expression profiling of normal and malignant breast epi-
thelia using three different approaches – two commonly
used technologies we had utilised previously [21] and a
recently released microarray designed specifically for
investigation of breast cancer.
To ensure fair comparison, a human transcriptome data-
base was used as a common mapping point for the three
technologies [22]. This produced similar numbers of
mapped features for the Plus 2.0 and Breast Cancer DSA
and markedly lower amounts for MPSS. The similar over-
all numbers of Plus 2.0 and DSA probesets unambigu-
ously mapping to the HTR database were contrasted when
Quantitative strand-specific RT-PCR analysis of SAS pair expression in breast cancer cell lines and solid primary breast  tumours Figure 4
Quantitative strand-specific RT-PCR analysis of SAS pair expression in breast cancer cell lines and solid pri-
mary breast tumours. cDNAs of 15 breast cancer cell lines and 10 primary breast tumours (BC) were analyzed using the 
ΔΔCT relative quantification real-time qPCR. Red bars represent sense transcripts, green bars the corresponding antisense 
transcripts. Analysis of qPCR data was performed using the immortalised luminal cell line (226L) as comparator for all the 
breast cell lines and solid primary breast tumours (indicates as BC). ACTB was used as endogenous control throughout all 
analysis. ΔΔCT relative quantification data are expressed as mean fold changes across samples together with 95% confidence 
intervals.
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the orientation of alignment was considered, with the
Plus 2.0 showing slightly higher numbers of sense features
and the DSA showing significantly higher numbers of
antisense transcripts. This is most likely explained by the
Plus 2.0 design being focused on common protein coding
genes from older public data while the DSA design
employed tissue specific sequencing and is more likely to
have discovered novel content. Therefore whilst the Plus
2.0 could be expected to have more features mapping in
the sense orientation, a proportion of these likely repre-
sent transcripts not necessarily of functional importance
in breast cancer.
The fact that MPSS produced fewer unambiguous maps
than either of the other two technologies is a reflection of
the short tag length utilised by the technology and the
consequent increased likelihood of cross hybridisation.
This fact highlights a major shortcoming of the MPSS
approach. Whereas either of the microarray technologies
utilise probesets containing eleven 25-mer probes and
specially formulated to be reflective of a single transcript,
the MPSS approach generates single tags only 21 nucle-
otides in length. This fact creates significant potential for
incorrect mapping of tags and means that much of the ini-
tial data generated becomes unusable when a stringent
mapping methodology is utilised. This serves as a general
reminder of the care that must be taken in the interpreta-
tion of any data generated on the basis of short, single tags
or probes.
Detection analysis showed further advantages of the DSA
approach with higher numbers of present calls than the
Plus 2.0 array in both orientations. The fact that this trend
was observed regardless of the Plus 2.0's higher number of
sense mapped features is again suggestive of the advantage
of the disease-focused approach used in the generation of
the DSA – it would appear that a larger proportion of the
Plus 2.0 content does not show expression in breast epi-
thelia. MPSS again under performed at this point, which
is reflective of previous assessments of the technology
[23].
Generic arrays have previously been suggested as a viable
means of studying antisense transcription [8,24] however
the higher number of antisense transcripts and higher
detection levels on the DSA suggest that antisense tran-
scription would be better studied using a focused
approach like the Breast Cancer DSA research tool. Fur-
thermore, the DSA achieved greater concordance with
MPSS data than the Plus 2.0 which is noteworthy as our
previous studies conducted in the absence of the DSA had
identified the Affymetrix Plus 2.0 as the microarray plat-
form that had the highest concordance with the MPSS
data set [20].
Our criteria for selection of a 'robust' set of antisense tran-
scripts meant that a large proportion (~90%) of the DSA's
antisense probesets were excluded from further analysis. It
is likely that some of these antisense transcripts arose due
to experimental artefacts [21] and the use of actinomycin
D during reverse transcription could have reduced the
number of antisense transcripts as seen in the study of Per-
occhi et al [25]. Nevertheless, it is equally possible that
many of these are probesets to genuine antisense
sequences and could have yielded useful data – 868 probe
sets on the DSA showed more than two fold differential
expression, however in the absence of an extended valida-
tion of the antisense transcripts it was felt that they should
only be considered when confirmed by one of the other
two technologies used in the study. This leaves a substan-
tial subset of remaining antisense transcripts whose
expression in the breast tissue has to be validated by dif-
ferent technologies in the future.
The 257 robust sense-antisense pairs investigated on the
DSA showed a high degree of novelty when compared to
a recently created SAS database, suggestive of the fact that
a large number of SAS pairs remain to be discovered and
reported. Numerous SAS databases have been published
by other researchers [7,26] and comparison with these
could form the basis of further studies. The large number
of novel SAS pairs identified here is understandable as the
discovery of antisense transcripts and SAS pairs is still con-
sidered a relatively new phenomenon in many quarters
and work in this area has yet to reach maturity. This pro-
vides further indication of the potential value of the anti-
sense transcripts represented on the DSA but excluded
from this study. The nature and function of the 431
'robust' antisense candidates and the subset of these form-
ing the 257 SAS pairs is currently unknown. As stated pre-
viously, the Breast Cancer DSA is a discovery platform
containing many transcripts that have not yet been well
characterised. Whilst we have demonstrated the expres-
sion of these antisense transcripts, extensive subsequent
validation would be required to elucidate their function
and falls outside the scope of the current study. Sequence
alignment data for the SAS pairs are provided [see Addi-
tional file 5] and may prove a useful resource for future
functional analysis.
SAS pairs have previously been classified as head-to-head,
tail-to-tail or embedded based on their pattern of overlap
[6]. A limitation of the DSA technology is that it utilises 3'
biased protocols and therefore only the 3' end of tran-
scripts are interrogated. As a result, SAS pairs discovered
using this technology will solely represent tail-to-tail over-
lap patterns. This fact also suggests that there may be a
large body of alternatively classified SAS pairs to be dis-
covered by other experimental means.BMC Genomics 2009, 10:324 http://www.biomedcentral.com/1471-2164/10/324
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The fact that all SAS pairs differentially expressed between
the normal and malignant settings showed positive corre-
lation was surprising as negative correlation has previ-
ously been reported in several studies [11]. This led us to
attempt validation of the SAS expression in a range of
malignant cell-lines and solid tumours by means of
strand-specific RT-PCR. The results produced by this
approach largely correlated with those obtained on the
DSA platform, however negative correlation was observed
in 13 of the 81 tested samples. So while our pooled sam-
ples suggested positive correlation of differential expres-
sion of all SAS pairs between normal and malignant
settings, individual assessment of a range of solid tumours
and cell-lines indicated the existence of alternative pat-
terns of differential expression. While differential expres-
sion of the sense and antisense transcript for MMP24 was
more prominent in luminal breast cancer cell lines (3/5),
significant different expression levels of the DCBLD2 -SAS
pair were observed solely in two luminal, hormone recep-
tor positive breast cancer cell lines. This data might sug-
gest that the level of expression for certain SAS pairs could
be breast cancer subtype specific. Nonetheless our studies
suggest that coexpression of SAS pairs may be more prev-
alent than inverse expression. The differing patterns of dif-
ferential expression between samples suggests a potential
functional relevance of sense-antisense expression pat-
terns as has previously been reported [11] and serves to
highlight the importance of SAS profiling in cancer
research. Such knowledge could be beneficial in the eluci-
dation of pathways in cancer and might be exploited in
potential future treatments like antisense therapy [27].
Aberrations in SAS expression patterns might well be
indicative of disease or could prove useful in sub-classifi-
cation of a given disease, potentially aiding in the devel-
opment of targeted treatments.
Conclusion
In conclusion, the data presented in this study demon-
strate a clear benefit in the use of a disease-focused plat-
form such as the Breast Cancer DSA research tool for
disease-specific studies. Utilising only a subset of the SAS
pair data available on the platform we have shown expres-
sion of several hundred SAS pairs, of which a large propor-
tion appear to be novel. We have also identified the
expression of many more antisense transcripts not identi-
fied by other means. These findings would suggest that
many more SAS pairs remain to be discovered and depos-
ited in public databases. RT-PCR has validated the expres-
sion of a selection of these SAS pairs and identified
patterns of SAS expression that support previous findings
and appear to suggest functional relevance. While much
of the work presented here is preliminary it still provides
a strong indication of the importance of SAS expression in
breast and other cancers and highlights that much investi-
gation is still required in this field of research.
Methods
Biological samples
RNA samples were isolated from two sources: one pool of
10 primary cultures (~107) of normal human breast lumi-
nal cells which were prepared from reduction mammo-
plasty samples by double immunomagnetic sorting
methods [28-30], and one pool of 16 primary breast
tumours substantially enriched for epithelial cells immu-
nomagentically purified using FAP antibody. RNA purity
and integrity was assessed with an Agilent 2100 Bioana-
lyzer (Agilent Technologies, Palo Alto, CA). Cell purifica-
tion procedures as well as details of the pathology of the
individual tumours have been described previously
[20,28-30]. The RNA extraction process was based on
standard Trizol methods, from which 100 μg per sample
for the luminal pool and 50 μg total RNA for the malig-
nant breast epithelial pool were used. All samples were
stored at -80°C until being used in experiments. Informed
consent was obtained to use this material for scientific
research.
MPSS, microarray and data processing
As described previously, both RNA pools were exploited
by MPSS experiments at Lynx-Therapeutics, Inc (now Illu-
mina, Hayward, CA) [31,32]. Briefly, following an RNA
quality test on an Agilent 2100 BioAnalyzer (Agilent Tech-
nologies, Palo Alto, CA), cDNA libraries were generated
from ~300 μg of DNase treated total RNA pools according
to the "signature" Megaclone protocol [31,32]. The result-
ing libraries were amplified and yielded ~2 x 106
microbeads. The sequence adjacent to the poly(A)+ prox-
imal DpnII site was determined by cycles of ligations to
fluorescently tagged "decoding" oligonucleotides and
cleavages by restriction enzymes. The abundance for each
signature tag in the two pools was represented as tran-
scripts per million (tpm), and sequence signatures seen in
at least two independent runs and present at a frequency
of at least 3 tpm in at least one sample were selected for
further analysis.
Gene expression data in the normal luminal epithelial
pool and the malignant breast epithelial pool was
retrieved for the Affymetrix HG-U133 Plus 2.0 GeneChip®
(Affymetrix, Santa Clara, CA) platform from our previous
study [20], as well as from the Almac Diagnostics Breast
Cancer DSA [18]. Microarray experiments for the latter
microarray platform were outsourced to ALMAC GROUP
LTD, UK, and hybridisations, scanning and primary data
acquisition were performed according to their manufac-
turer's protocols. Three technical replicates were obtained
for each RNA pool. Briefly, 2 μg total RNA was reverse
transcribed with a poly-(T) primer containing a T7 pro-
moter, and the cDNA made double-stranded. An in vitro
transcription was done to produce biotinylated cRNA,
which was then hybridized to the GeneChips. The chipsBMC Genomics 2009, 10:324 http://www.biomedcentral.com/1471-2164/10/324
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were washed and stained with streptavidin phycoerythrin
using an Affymetrix FS-450 fluidics station, and data was
collected with Affymetrix GeneChip Scanner 3000.
All data can be found on the ArrayExpress [33] website
under E-TABM-657.
Pre-processing methods included normalisation and
transformation, which were performed in the R-environ-
ment [34]. Since the Breast Cancer DSA is based on the
Affymetrix GeneChip technology, normalisation and
transformation of the raw data was performed using the
robust multi-array analysis (RMA) [35] to obtain relative
measurements for each probe sets. Secondly, analysis was
performed on the Breast Cancer DSA with the Affymetrix
Microarray Suite version 5 (MAS5) algorithms, which uses
the probe-pair data to calculate the detection call. Based
on a non-parametric Wilcoxon signed rank test of whether
significantly more perfect matches show more hybridiza-
tion signal than their corresponding mismatches to pro-
duce the detection call, MAS5 determines the absence or
presence state for each probe sets [36].
Matching of transcripts among microarray platforms and 
between MPSS and microarrays
A sequence-based approach was taken to match features
across all different platforms. MPSS tags and microarray
probes for the Breast Cancer DSA and Plus 2.0 were
mapped to the Human Transcriptome (HTR) database
developed by Iseli et al. [37-39] using the tagger software
developed by Iseli. The mapping search was performed
against both strands of the HTR database sequences to
enable detection of both sense and antisense matches.
Perfect homology was required across all 17 bases of the
MPSS tags to produce a positive mapping. All 17 base tags
began with the four base combination 'GATC' to ensure
that all matches occurred immediately downstream of a
DpnII site. Microarray probes required perfect homology
across all of their 25 bases to produce a positive match. A
probe set (generally comprising 11 probes) required at
least 5 probes to match a sequence in the same orientation
to produce a positive mapping. HTR database cluster
identifiers were retrieved for all positive matches. Further-
more, all microarray features that mapped to more than
one HTR cluster were excluded from further analysis to
avoid the one: many scenario where a microarray feature
was linked to more than one HTR cluster, resulting in
matches with multiple different microarray features of
other platforms or multiple MPSS tags. However, several
microarray features could map to the same HTR cluster,
not only to avoid considerate reduction of the data, but
also to have differentially regulated transcript isoforms
represented.
SAS pairs on Breast Cancer DSA
Full sequences used in the creation of the Breast Cancer
DSA and the sequences of the 431 HTR clusters had low
complexity regions and repeats masked using Paracel Fil-
tering Package (Paracel inc. now Striking Development)
[40]. The Exonerate software [41] was used to align the
DSA sequences to the HTR clusters (score threshold 200
and ID threshold 90%) and custom PERL scripts used to
process the output and search for overlap of sequences in
sense-antisense orientation.
The database created by Galante et al. was obtained from
the LICR Sense/Antisense portal [42] and formatted as a
Paracel Blast database [40] Breast Cancer DSA probe selec-
tion regions for the SAS pairs where then blasted against
the database. An alignment of 50% query length coverage
and 90% identity was required to be considered a positive
result. SAS pairs were considered to be novel when none
of the probe selection regions representing them pro-
duced a positive alignment result.
Strand-specific reverse transcription PCR (RT-PCR) 
analysis of cell lines and breast tumour samples
To determine fold changes in expression of a selected
group of SAS pairs, quantitative real time PCR (qPCR)
reactions were carried out as described by Sleeman et al.
[43], using the ΔΔCT relative quantification method. The
panel of breast cell lines comprised: 1098L, BT20, BT474,
CAMA-1, GI101, HMT3552, Hs578T, MCF7,
MDAMB231, MDAMB453, MDAMB468, PMC42, SKBR5,
SKBR7, T47D and ZR75 and were a kind gift of Prof. Mike
O'Hare. Ten infiltrating ductal carcinomas of histological
grade 2 and 3 were retrieved from the Middlesex, UCL
Hospital before 1996 and informed consent to use this
material for scientific research was obtained. 100 ng of
RNA was used to generate two independent cDNA synthe-
ses for all samples using Omniscript Reverse Transcripion
Kit (Qiagen, UK) as per manufacturer's guidelines. Prim-
ers for reverse transcription were designed to be gene and
strand specific for both the sense and anti-sense strand
(PrimerDesign Ltd, UK) for DCBLD2, MMP24 and
KRT81. Analysis of qPCR data was performed using the
immortalised luminal cell line (226L) as comparator for
all the breast cell lines and solid tumours [see Additional
file 6]. ACTB was used as endogenous control throughout
all analysis. ΔΔCT relative quantification data are
expressed as mean fold changes across samples together
with 95% confidence intervals.
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